Q&A: Page 2
Exclusive interviews with industry leaders
-
The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech
Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.
Michael Gibney • Nov. 28, 2023 -
Organon’s chief medical officer wants to change how the world sees women’s health
Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.
Michael Gibney • Nov. 22, 2023 -
AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?
Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.
Michael Gibney • Nov. 16, 2023 -
23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’
23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.
Alexandra Pecci • Nov. 7, 2023 -
Wisp’s ‘bold and unapologetic approach’ to women’s sexual and reproductive health
In the role of interim CEO of Wisp, Monica Cepak aims to break down barriers and expand access via telehealth.
Alexandra Pecci • Oct. 31, 2023 -
Red Jacket: Dr. Mark Goldberg, a clinical innovator
Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.
Alexandra Pecci • Oct. 27, 2023 -
Red Jacket: Dr. Jeremy Levin, a transformational leader
A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.
Michael Gibney • Oct. 27, 2023 -
Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.
Meagan Parrish • Oct. 27, 2023 -
Red Jacket: Ken Getz, a champion of clinical trials
Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.
Alexandra Pecci • Oct. 27, 2023 -
Red Jacket: Adele Gulfo, a commercialization guru
With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.
Karissa Waddick • Oct. 27, 2023 -
Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’
The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.
Michael Gibney • Oct. 19, 2023 -
To close the pediatric innovation gap, this biotech has to think differently
Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.
Alexandra Pecci • Oct. 11, 2023 -
5 minutes with — IDEA Pharma’s Mike Rea
The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.
Meagan Parrish • Oct. 11, 2023 -
Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant
Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.
Karissa Waddick • Sept. 27, 2023 -
Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’
The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.
Alexandra Pecci • Sept. 26, 2023 -
As the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
Michael Gibney • Sept. 21, 2023 -
In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
Michael Gibney • Sept. 14, 2023 -
‘We need to do better:’ A biotech CEO on standing apart from the crowd
The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.
Michael Gibney • Aug. 29, 2023 -
A leading Democrat reveals how his mental health struggles shape his policy approach
Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.
Karissa Waddick • Aug. 17, 2023 -
Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine
The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.
Kelly Bilodeau • Aug. 14, 2023 -
5 minutes with — Lundbeck CEO Dr. Deborah Dunsire
The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.
Meagan Parrish • Aug. 11, 2023 -
Why AbbVie’s former president has high hopes for this Flagship-backed biotech
The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.
Karissa Waddick • Aug. 7, 2023 -
How CymaBay overcame a NASH failure for another shot at liver disease success
The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.
Michael Gibney • Aug. 2, 2023 -
With OTC birth control approved, access battles have just begun
Perrigo received the first FDA approval for an OTC birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.
Karissa Waddick • July 26, 2023 -
In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets
Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.
Alexandra Pecci • July 25, 2023